Role of Mdm2 acid domain interactions in recognition and ubiquitination of the transcription factor IRF-2

Biochemical Journal

Volumn 418, Issue 3, 2009, Pages 575-585

  Pettersson, Susanne ^a   Kelleher, Michael ^a   Pion, Emmanuelle ^a   Wallace, Maura ^b   Ball, Kathryn L ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Acid domain; E3 ligase mechanism; Interferon regulatory factor 2 (IRF 2); Murine double minute 2 (Mdm2); p53; Ubiquitination signal

Indexed keywords

E3-LIGASE MECHANISM; INTERFERON REGULATORY FACTOR-2 (IRF-2); MURINE DOUBLE MINUTE 2 (MDM2); P53; UBIQUITINATION SIGNAL;

ACIDS; ANTIBIOTICS; BINDING ENERGY; BIOINFORMATICS; DOCKING; ENZYMES; GLYCOPROTEINS; HYDROPHOBICITY; LIGANDS; NUCLEIC ACIDS; SUBSTRATES; TRANSCRIPTION; TRANSCRIPTION FACTORS; TUMORS;

BINDING SITES;

INTERFERON REGULATORY FACTOR 2; PROTEIN MDM2; UBIQUITIN PROTEIN LIGASE E3; MDM2 PROTEIN, MOUSE; UBIQUITIN PROTEIN LIGASE;

ARTICLE; BINDING SITE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HYDROPHOBICITY; MOLECULAR DOCKING; OPEN READING FRAME; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; UBIQUITINATION; ANIMAL; BIOLOGY; CHEMISTRY; DRUG ANTAGONISM; GENETICS; METABOLISM; MOUSE; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE;

MURINAE;

ANIMALS; COMPUTATIONAL BIOLOGY; INTERFERON REGULATORY FACTOR-2; MICE; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-MDM2; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION;

EID: 62149124822     PISSN: 02646021     EISSN: 14708728     Source Type: Journal    
DOI: 10.1042/BJ20082087     Document Type: Article

References (37)

1. Vousden, K. H. and Lane, D. P. (2007) p53 in health and disease. Nat. Rev. Mol. Cell Biol. 8, 275-283
2. Hupp, T. R. and Walkinshaw, M. (2007) Multienzyme assembly of a p53 transcription complex. Nat. Struct. Mol. Biol. 14, 885-887
3. Bond, G. L., Hu, W. and Levine, A. J. (2005) MDM2 is a central node in the p53 pathway: 12 years and counting. Curr. Cancer Drug Targets 5, 3-8
4. Zhang, Z. and Zhang, R. (2005) p53-independent activities of MDM2 and their relevance to cancer therapy. Curr. Cancer Drug Targets 5, 9-20
5. Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J. and Pavletich, N. P. (1996) Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274, 948-953
6. Shimizu, H., Burch, L. R., Smith, A. J., Dornan, D., Wallace, M., Ball, K. L. and Hupp, T. R. (2002) The conformationally flexible S9-S10 linker region in the core domain of p53 contains a novel MDM2 binding site whose mutation increases ubiquitination of p53 in vivo. J. Biol. Chem. 277, 28446-28458
7. Wallace, M., Worrall, E., Pettersson, S., Hupp, T. R. and Ball, K. L. (2006) Dual-site regulation of MDM2 E3-ubiquitin ligase activity. Mol. Cell 23, 251-263
8. Yu, G. W., Rudiger, S., Veprintsev, D., Freund, S., Fernandez-Fernandez, M. R. and Fersht, A. R. (2006) The central region of HDM2 provides a second binding site for p53. Proc. Natl. Acad. Sci. U.S.A. 103, 1227-1232
9. Terzian, T., Suh, Y. A., Iwakuma, T., Post, S. M., Neumann, M., Lang, G. A., Van Pelt, C. S. and Lozano, G. (2008) The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev. 22, 1337-1344
10. Taniguchi, T., Ogasawara, K., Takaoka, A. and Tanaka, N. (2001) IRF family of transcription factors as regulators of host defense. Annu. Rev. Immunol. 19, 623-655
11. Pamment, J., Ramsay, E., Kelleher, M., Dornan, D. and Ball, K. L. (2002) Regulation of the IRF-1 tumour modifier during the response to genotoxic stress involves an ATM-dependent signalling pathway. Oncogene 21, 7776-7785
12. Gannon, J. V., Greaves, R., Iggo, R. and Lane, D. P. (1990) Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J. 9, 1595-1602
13. Wawrzynow, B., Zylicz, A., Wallace, M., Hupp, T. and Zylicz, M. (2007) MDM2 chaperones the p53 tumor suppressor. J. Biol. Chem. 282, 32603-32612
14. Treier, M., Staszewski, L. M. and Bohmann, D. (1994) Ubiquitin-dependent c-Jun degradation in vivo is mediated by the delta domain. Cell 78, 787-798
15. Honda, R., Tanaka, H. and Yasuda, H. (1997) Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 420, 25-27
16. Lai, Z., Ferry, K. V., Diamond, M. A., Wee, K. E., Kim, Y. B., Ma, J., Yang, T., Benfield, P. A., Copeland, R. A. and Auger, K. R. (2001) Human mdm2 mediates multiple mono-ubiquitination of p53 by a mechanism requiring enzyme isomerization. J. Biol. Chem. 276, 31357-31367
17. Poyurovsky, M. V., Priest, C., Kentsis, A., Borden, K. L., Pan, Z. Q., Pavletich, N. and Prives, C. (2007) The Mdm2 RING domain C-terminus is required for supramolecular assembly and ubiquitin ligase activity. EMBO J. 26, 90-101
18. Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C. et al. (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844-848
19. Dornan, D. and Hupp, T. R. (2001) Inhibition of p53-dependent transcription by BOX-I phospho-peptide mimetics that bind to p300. EMBO Rep. 2, 139-144
20. Buolamwini, J. K., Addo, J., Kamath, S., Patil, S., Mason, D. and Ores, M. (2005) Small molecule antagonists of the MDM2 oncoprotein as anticancer agents. Curr. Cancer Drug Targets 5, 57-68
21. Shimizu, H. and Hupp, T. R. (2003) Intrasteric regulation of MDM2. Trends Biochem. Sci. 28, 346-349
22. Schon, O., Friedler, A., Bycroft, M., Freund, S. M. and Fersht, A. R. (2002) Molecular mechanism of the interaction between MDM2 and p53. J. Mol. Biol. 323, 491-501
23. Meulmeester, E., Frenk, R., Stad, R., de Graaf, P., Marine, J. C., Vousden, K. H. and Jochemsen, A. G. (2003) Critical role for a central part of Mdm2 in the ubiquitylation of p53. Mol. Cell. Biol. 23, 4929-4938
24. Kawai, H., Wiederschain, D. and Yuan, Z. M. (2003) Critical contribution of the MDM2 acidic domain to p53 ubiquitination. Mol. Cell. Biol. 23, 4939-4947
25. Kulikov, R., Winter, M. and Blattner, C. (2006) Binding of p53 to the central domain of Mdm2 is regulated by phosphorylation. J. Biol. Chem. 281, 28575-28583
26. Midgley, C. A., Desterro, J. M., Saville, M. K., Howard, S., Sparks, A., Hay, R. T. and Lane, D. P. (2000) An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo. Oncogene 19, 2312-2323
27. Zhang, Y. and Xiong, Y. (2001) Control of p53 ubiquitination and nuclear export by MDM2 and ARF. Cell Growth Differ. 12, 175-186
28. Stad, R., Little, N. A., Xirodimas, D. P., Frenk, R., van der Eb, A. J., Lane, D. P., Saville, M. K. and Jochemsen, A. G. (2001) Mdmx stabilizes p53 and Mdm2 via two distinct mechanisms. EMBO Rep. 2, 1029-1034
29. Badciong, J. C. and Haas, A. L. (2002) MdmX is a RING finger ubiquitin ligase capable of synergistically enhancing Mdm2 ubiquitination. J. Biol. Chem. 277, 49668-49675
30. Linares, L. K., Hengstermann, A., Ciechanover, A., Muller, S. and Scheffner, M. (2003) HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53. Proc. Natl. Acad. Sci. U.S.A. 100, 12009-12014
31. Bothner, B., Lewis, W. S., DiGiammarino, E. L., Weber, J. D., Bothner, S. J. and Kriwacki, R. W. (2001) Defining the molecular basis of Arf and Hdm2 interactions. J. Mol. Biol. 314, 263-277
32. Remaut, H. and Waksman, G. (2006) Protein-protein interaction through β-strand addition. Trends Biochem. Sci. 31, 436-444
33. Linares, L. K. and Scheffner, M. (2003) The ubiquitin-protein ligase activity of Hdm2 is inhibited by nucleic acids. FEBS Lett. 554, 73-76
34. Elenbaas, B., Dobbelstein, M., Roth, J., Shenk, T. and Levine, A. J. (1996) The MDM2 oncoprotein binds specifically to RNA through its RING finger domain. Mol. Med. 2, 439-451
35. Senger, K., Merika, M., Agalioti, T., Yie, J., Escalante, C. R., Chen, G., Aggarwal, A. K. and Thanos, D. (2000) Gene repression by coactivator repulsion. Mol. Cell 6, 931-937
36. Stellacci, E., Testa, U., Petrucci, E., Benedetti, E., Orsatti, R., Feccia, T., Stafsnes, M., Coccia, E. M., Marziali, G. and Battistini, A. (2004) Interferon regulatory factor-2 drives megakaryocytic differentiation. Biochem. J. 377, 367-378
37. Passioura, T., Shen, S., Symonds, G. and Dolnikov, A. (2005) A retroviral library genetic screen identifies IRF-2 as an inhibitor of N-Ras-induced growth suppression in leukemic cells. Oncogene 24, 7327-7336